Table 1.

Selected prospective randomized trials evaluating GnRHa as therapy for symptomatic endometriosis

Reference	GnRHa	N	Dose	Route of Administration	Control	Duration	Follow-up
6	Nafarelin	213	400–800 μg	IN daily	Danazol 800 mg	6 mo	—
7	Nafarelin	82	400 μg	IN daily	Danazol 600 mg	6 mo	3 mo
9	Nafarelin	307	400 μg	IN daily	Danazol 600 mg	6 mo	1 y
10	Buserelin	36	0.2 mg 1.2 mg	SC daily IN daily	Danazol 800 mg	6 mo	—
11	Triptorelin	49	3.75 mg	IM every 4 wk	Placebo	6 mo	12 mo (5 patients)
12	Leuprolide	52	3.75 mg	IM every 4 wk	Placebo	6 mo	1 y (24 patients)
13	Goserelin	315	3.6 mg	SC every 4 wk	Danazol 800 mg	24 wk	48 wk BMD only (58 patients)
14	Goserelin	307	3.6 mg	SC every 4 wk	Danazol 600 mg	24 wk	24 wk
16	Goserelin	57	3.6 mg	SC every 4 wk	OC	24 wk	24 wk
17	Nafarelin	183	400 μg	IN daily	Leuprolide 3.75 mg	24 wk	24 wk BMD only

IN = intranasal, SC = subcutaneous, IM = intramuscular, OC = Monophasic oral contraceptive (ethinyl estradiol 0.02 mg and desogestrel 0.15 mg), BMD = bone mineral density.